Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 24;7(10):ofaa454. doi: 10.1093/ofid/ofaa454

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 1. — Weight change after switch to emtricitabine/tenofovir alafenamide (F/TAF). Plot of the patient’s weight diary from September 2, 2019 to June 18, 2020. Daily weights before September 2, 2019 were unavailable (discarded previously). At the time of the switch to F/TAF, he had been on emtricitabine/tenofovir disoproxil fumurate (F/TDF) for 20.3 months. Green line represents the switch from F/TDF to F/TAF. Red line represents the switch from F/TAF back to F/TDF.